Phase 3 Diffuse Large B Cell Lymphoma Clinical Trials

15 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 115 of 15 trials

Recruiting
Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled263 locationsNCT06717347
Recruiting
Phase 2Phase 3

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled132 locationsNCT05139017
Recruiting
Phase 3

Study of Out of Specification for Tisagenlecleucel

Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals200 enrolled53 locationsNCT04094311
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled175 locationsNCT01804686
Recruiting
Phase 3

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLymphoma, B-Cell+6 more
Lyell Immunopharma, Inc.400 enrolled38 locationsNCT07188558
Recruiting
Phase 3

The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

Diffuse Large B Cell Lymphoma
Ruijin Hospital640 enrolled1 locationNCT05018520
Recruiting
Phase 3

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

DLBCL - Diffuse Large B Cell Lymphoma
Stichting Hemato-Oncologie voor Volwassenen Nederland324 enrolled25 locationsNCT06220032
Recruiting
Phase 3

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.280 enrolled2 locationsNCT06929624
Recruiting
Phase 3

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Diffuse Large B Cell LymphomaDLBCL
Nordic Lymphoma Group300 enrolled69 locationsNCT04332822
Recruiting
Phase 3

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma
Ruijin Hospital100 enrolled1 locationNCT06522555
Recruiting
Phase 3

Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell LymphomaLarge B-cell Lymphoma
Universität des Saarlandes330 enrolled17 locationsNCT05820841
Recruiting
Phase 3

Genotype-guided Treatment in DLBCL

Diffuse Large B Cell Lymphoma
Ruijin Hospital1,100 enrolled1 locationNCT05351346
Recruiting
Phase 3

Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Diffuse Large B Cell LymphomaElderly Patients
Fondazione Italiana Linfomi - ETS430 enrolled49 locationsNCT04442412
Recruiting
Phase 3

Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line

Diffuse Large B Cell Lymphoma
Weprom186 enrolled5 locationsNCT04670029
Active
Phase 3

Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With Diffuse Large B cell Lymphoma (DLBCL) and Treated With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)

Diffuse large B cell lymphoma (DLBCL) in elderly patients
Australasian Leukaemia and Lymphoma Group80 enrolled3 locationsACTRN12611000085976